Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

被引：7
作者：
Heerspink, Hiddo J. L. [1 ]
机构：
[1] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2019年 / 34卷 / 12期
关键词：
TYPE-2; DIABETES-MELLITUS; DAPAGLIFLOZIN; EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1093/ndt/gfz033
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：2015 / 2017
页数：3
相关论文
共 18 条
  • [1] Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus
    Bays, Harold E.
    Weinstein, Richard
    Law, Gordon
    Canovatchel, William
    [J]. OBESITY, 2014, 22 (04) : 1042 - 1049
  • [2] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    Bolinder, Jan
    Ljunggren, Osten
    Kullberg, Joel
    Johansson, Lars
    Wilding, John
    Langkilde, Anna Maria
    Sugg, Jennifer
    Parikh, Shamik
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) : 1020 - 1031
  • [3] The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
    Cherney, David
    Lund, Soren S.
    Perkins, Bruce A.
    Groop, Per-Henrik
    Cooper, Mark E.
    Kaspers, Stefan
    Pfarr, Egon
    Woerle, Hans J.
    von Eynatten, Maximilian
    [J]. DIABETOLOGIA, 2016, 59 (09) : 1860 - 1870
  • [4] Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
    Cherney, David Z. I.
    Cooper, Mark E.
    Tikkanen, Ilkka
    Pfarr, Egon
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Lund, Soren S.
    [J]. KIDNEY INTERNATIONAL, 2018, 93 (01) : 231 - 244
  • [5] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
    Cherney, David Z. I.
    Perkins, Bruce A.
    Soleymanlou, Nima
    Maione, Maria
    Lai, Vesta
    Lee, Alana
    Fagan, Nora M.
    Woerle, Hans J.
    Johansen, Odd Erik
    Broedl, Uli C.
    von Eynatten, Maximilian
    [J]. CIRCULATION, 2014, 129 (05) : 587 - 597
  • [6] Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
    Heerspink, H. J. L.
    Johnsson, E.
    Gause-Nilsson, I.
    Cain, V. A.
    Sjostrom, C. D.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (06) : 590 - 597
  • [7] Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
    Heerspink, Hiddo J. L.
    Desai, Mehul
    Jardine, Meg
    Balis, Dainius
    Meininger, Gary
    Perkovic, Vlado
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (01): : 368 - 375
  • [8] Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
    Heerspink, Hiddo J. L.
    Perkins, Bruce A.
    Fitchett, David H.
    Husain, Mansoor
    Cherney, David Z. I.
    [J]. CIRCULATION, 2016, 134 (10) : 752 - 772
  • [9] Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
    Layton, A. T.
    Vallon, V.
    [J]. ACTA PHYSIOLOGICA, 2018, 222 (04)
  • [10] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 644 - 657
12